The U.S. Food and Drug Administration (FDA) has approved Adbry TM (tralokinumab-ldrm) for the treatment of moderate to severe atopic dermatitis in adults 18 years of age and older. Adbry can be given with or without topical corticosteroids. To better understand what adbry is, what Adbry does, let's learn more in the article below.